Patents by Inventor Rita De Santis
Rita De Santis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210128740Abstract: The present invention relates to novel Histone Deacetylase Inhibitors (HDACi)-based antibody drug conjugates particularly with antibodies directed to ErbB, ErbB2 and ErbB3 receptors, pharmaceutical compositions comprising said antibodies as well as to their use in the treatment of cancer or tumor and other diseases where a modulation of one or more histone deacetylase isoforms can be effective for therapeutic interventions.Type: ApplicationFiled: March 27, 2018Publication date: May 6, 2021Applicant: ALFASIGMA S.P.A.Inventors: Loredana Vesci, Rita De Santis, Ferdinando Maria Milazzo, Giuseppe Giannini, Maurizio Taddei, Valentina Faltoni, Elena Petricci
-
Patent number: 9872831Abstract: The present invention describes oxidized avidin, suitable for inhalation, for conditioning the lung affected by inoperable/diffuse diseases, enabling the targeted delivery of biotinylated therapeutic agents to it.Type: GrantFiled: July 25, 2012Date of Patent: January 23, 2018Assignee: ALFASIGMA S.P.A.Inventor: Rita De Santis
-
Publication number: 20140134106Abstract: The present invention describes oxidized avidin, suitable for inhalation, for conditioning the lung affected by inoperable/diffuse diseases, enabling the targeted delivery of biotinylated therapeutic agents to it.Type: ApplicationFiled: July 25, 2012Publication date: May 15, 2014Applicant: SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A.Inventor: Rita De Santis
-
Patent number: 8562947Abstract: The present invention describes chemically modified avidins that have higher permanence in treated tissues compared to wild type avidin. Avidin oxidation is performed by periodate incubation in the presence of the low affinity ligand HABA which, occupying the biotin binding sites, prevents protein denaturation during the oxidation step. Periodate oxidation generates CHO groups from avidin mannose ring opening that, once injected, react with tissue NH2 residues to form stable Schiff's bases. The anchored avidins maintain the ability to bind biotinylated agents endowed of therapeutic activity, like radiolabeled biotins, stem cells and somatic cells, useful for brachytherapies like Intraoperative Avidination Radionuclide Therapy (IART®) or degenerative or genetic diseases.Type: GrantFiled: July 16, 2008Date of Patent: October 22, 2013Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventors: Rita De Santis, Carlo Antonio Nuzzolo
-
Publication number: 20130122033Abstract: A engineered bacteriophage is herein described, displaying at its surface multiple copies of a polypeptide, which comprises a domain of the bacterial adhesion protein FimH fused with the coat protein pVIII. The domain is preferably the region 45-159aa of the mature protein FimH. The polypeptide beingantigenic, raises a desired immunological response, in particular against urinary tract infections (UTI) in a human or animal. The engineered bacteriophage is therefore suitable for the preparation of vaccinesfor therapy, diagnosis and/or prevention of urinary tract infections (UTI) in a human or animal.Type: ApplicationFiled: June 28, 2011Publication date: May 16, 2013Inventors: Rita De Santis, Olga Minenkova
-
Patent number: 8318911Abstract: An anti-EpCAM antibody, designated ST3232/10, of marine origin exhibits properties suitable for both therapeutic and diagnostic applications. It shows high affinity for the native antigen and good tumor selectivity.Type: GrantFiled: April 2, 2008Date of Patent: November 27, 2012Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventors: Anna Maria Anastasi, Fiorella Petronzelli, Rita De Santis, Saverio Alberti
-
Publication number: 20120237524Abstract: Met inhibitor and/or nucleotide sequence encoding a Met inhibitor for use in the treatment of patients suffering from a cancer for reducing and/or abrogating patients' resistance to radiotherapy, wherein the Met inhibitor is selected among: i) an anti-Met monoclonal antibody, ii) a genetically engineered antibody containing the complementarity determining regions (CDRs) of the anti-Met monoclonal antibody, and iii) a fragment of (i) or (ii) containing the complementarity determining regions (CDRs) of the anti-Met monoclonal antibody, or combinations thereof.Type: ApplicationFiled: March 19, 2012Publication date: September 20, 2012Inventors: Carla Boccaccio, Paolo Maria Comoglio, Fiorella Petronzelli, Rita De Santis
-
Patent number: 7989171Abstract: An anti-human tenascin monoclonal antibody is described, whose light and heavy chain variable region sequences are SEQ ID 1 and SEQ ID 2, respectively, its proteolytic fragments capable of binding to an antigenic epitope within the region A(1-4)-D of human tenascin, its recombinant derivatives, its conjugates and its similar functional analogues capable of binding to an antigenic epitope within the A(1-4)-D region of human tenascin.Type: GrantFiled: February 16, 2005Date of Patent: August 2, 2011Assignee: Tecnogen S.C.P.A.Inventors: Rita De Santis, Angela Pelliccia, Giovanna Palombo, Paolo Carminati
-
Patent number: 7883889Abstract: The present invention discloses a method of generation of antigen presenting cells, comprising: a collecting said cells from a subject, b. activating said collected cells; c. culturing and optionally expanding ex vivo said activated cells; d. treating said cultured and optionally expanded cells with DNA hypomethylating agents so that said cells concomitantly express multiple tumor associated antigens. The cells obtainable according to the method of the present invention, as well as the cellular components thereof whether alone or in combination with said cells, are useful for prevention and treatment of malignancies of different histotype that constitutively express one or more of the multiple tumor associated antigens that are expressed in said cells. Conveniently, said cells and/or cellular components are in the form of a vaccine. Said vaccines are advantageous over the prior art in that as they concomitantly express multiple/all methylation-regulated tumor associated antigens.Type: GrantFiled: July 25, 2002Date of Patent: February 8, 2011Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventor: Rita De Santis
-
Publication number: 20100297003Abstract: An anti-human tenascin monoclonal antibody is described, whose light and heavy chain variable region sequences are SEQ ID 1 and SEQ ID 2, respectively, its proteolytic fragments capable of binding to an antigenic epitope within the region A(1-4)-D of human tenascin, its recombinant derivatives, its conjugates and its similar functional analogues capable of binding to an antigenic epitope within the A(1-4)-D region of human tenascin.Type: ApplicationFiled: February 16, 2005Publication date: November 25, 2010Applicant: TECNOGEN S.C.P.A.Inventors: Rita De Santis, Angela Pelliccia, Giovanna Palombo, Paolo Carminati
-
Patent number: 7833981Abstract: Deglycosylated long pentraxin PTX3 and desialidated long pentraxin PTX3 are disclosed, as well as processes for their preparation, pharmacological compositions containing them, and their use for the preparation of a medicament for the treatment of diseases in which the use of the long pentraxin PTX is indicated, particularly infectious and inflammatory diseases and female fertility disorders. These proteins are endowed with therapeutic activity superior to that of glycosylated pentraxin.Type: GrantFiled: February 23, 2010Date of Patent: November 16, 2010Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventors: Rita De Santis, Giovanni Salvatori, Paolo Carminati, Antonio Inforzato
-
Publication number: 20100209442Abstract: Deglycosylated long pentraxin PTX3 and desialidated long pentraxin PTX3 are disclosed, as well as processes for their preparation, pharmacological compositions containing them, and their use for the preparation of a medicament for the treatment of diseases in which the use of the long pentraxin PTX is indicated, particularly infectious and inflammatory diseases and female fertility disorders. These proteins are endowed with therapeutic activity superior to that of glycosylated pentraxin.Type: ApplicationFiled: February 23, 2010Publication date: August 19, 2010Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.Inventors: Paolo Carminati, Rita De Santis, Antonio Inforzato, Giovanni Salvatori
-
Publication number: 20100092491Abstract: An anti-EpCAM antibody, designated ST3232/10, of marine origin exhibits properties suitable for both therapeutic and diagnostic applications. It shows high affinity for the native antigen and good tumour selectivity.Type: ApplicationFiled: April 2, 2008Publication date: April 15, 2010Inventors: Anna Anastasi, Fiorella Petronzelli, Rita De Santis, Saverio Alberti
-
Patent number: 7683032Abstract: Deglycosylated long pentraxin PTX3 and desialidated long pentraxin PTX3 are disclosed, as well as processes for their preparation, pharmacological compositions containing them, and their use for the preparation of a medicament for the treatment of diseases in which the use of the long pentraxin PTX is indicated, particularly infectious and inflammatory diseases and female fertility disorders. These proteins are endowed with therapeutic activity superior to that of glycosylated pentraxin.Type: GrantFiled: September 28, 2005Date of Patent: March 23, 2010Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventors: Paolo Carminati, Rita De Santis, Antonio Inforzato, Giovanni Salvatori
-
Publication number: 20090110666Abstract: The invention described herein refers to derivatives of the long pentraxin PTX3 with the sequence indicated in the text, capable of binding to the membranes of inactivated tumour cells. The inactivated tumour cells, bearing on their surface a derivative of PTX3 are used to prepare an autologous vaccine for the treatment of tumours.Type: ApplicationFiled: February 25, 2003Publication date: April 30, 2009Inventors: Rita De Santis, Salvatori Giovanni
-
Patent number: 7438908Abstract: A novel anti-human tenascin ST2146 monoclonal antibody is described endowed with high affinity with the native antigen and high tumor selectivity. The cST2146 hybridoma is stably producing the antibody in high density culture conditions and is suitable for the industrial development of ST2146-based products. ST2146 exhibits properties exploitable for both therapeutic and diagnostic applications.Type: GrantFiled: February 20, 2003Date of Patent: October 21, 2008Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventors: Rita De Santis, Anna Maria Anastasi
-
Patent number: 7425317Abstract: Dimers of avidin and streptavidins (diavidins) are described wherein the linker is suberate, which in turn, is bound to different functional groups (—NH2 o-COOH) of avidin. As compared to avidin, the diavidins have shown the ability to increase the amount of labelled biotin on the target, when used in an in vitropretargeting test using supported human tenascin, the biotinylated anti-tenascin monoclonal antibody (Mab-B), avidin/diavidin, and biotin-3H. The use of such diavidins is also described in cancer diagnosis and anticancer therapy based on the three-step pretargeted radioimmunotherapy procedure.Type: GrantFiled: March 6, 2003Date of Patent: September 16, 2008Assignee: Sigma-Tau Industrie FarmaceuticheInventors: Rita De Santis, Ragnar Lindstedt, Carlo Nuzzolo
-
Publication number: 20070249021Abstract: Deglycosylated long pentraxin PTX3 and desialidated long pentraxin PTX3 are disclosed, as well as processes for their preparation, pharmacological compositions containing them, and their use for the preparation of a medicament for the treatment of diseases in which the use of the long pentraxin PTX is indicated, particularly infectious and inflammatory diseases and female fertility disorders. These proteins are endowed with therapeutic activity superior to that of glycosylated pentraxin.Type: ApplicationFiled: September 28, 2005Publication date: October 25, 2007Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.Inventors: Paolo Carminati, Rita De Santis, Antonio Inforzato, Giovanni Salvatori
-
Publication number: 20050026980Abstract: The present invention discloses a method for treating a subject affected by an autoimmune disease, in particular multiple sclerosis, lupus erythematosus systemicus and rheumatoid arthritis, comprising administering to said subject an effective amount of 3-(2-ethylphenyl)-5-methoxy-1H-1,2,4-tirazole. The present invention further discloses a method for inhibiting ?? T cells in a subject in need thereof, said method comprising administering to said subject an effective amount of the same compound.Type: ApplicationFiled: March 30, 2004Publication date: February 3, 2005Applicant: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventors: Luca Battistini, Giovanna Borsellino, Rita De Santis, Paolo Carminati
-
Publication number: 20050002920Abstract: The present invention discloses a method of generation of antigen presenting cells, comprising: a. collecting said cells from a subject, b. activating said collected cells; c. culturing and optionally expanding ex vivo said activated cells; d. treating said cultured and optionally expanded cells with DNA hypomethylating agents so that said cells concomitantly express multiple tumor associated antigens. The cells obtainable according to the method of the present invention, as well as the cellular components thereof whether alone or in combination with said cells, are useful for prevention and treatment of malignancies of different histotype that constitutively express one or more of the multiple tumor associated antigens that are expressed in said cells. Conveniently, said cells and/or cellular components are in the form of a vaccine. Said vaccines are advantageous over the prior art in that as they concomitantly express multiple/all methylation-regulated tumor associated antigens.Type: ApplicationFiled: July 26, 2004Publication date: January 6, 2005Applicant: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventor: Rita De Santis